{"id":532684,"date":"2021-08-31T08:03:56","date_gmt":"2021-08-31T12:03:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/"},"modified":"2021-08-31T08:03:56","modified_gmt":"2021-08-31T12:03:56","slug":"immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/","title":{"rendered":"Immutep\u2019s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">Sydney, Aug.  31, 2021  (GLOBE NEWSWIRE) &#8212; <b>SYDNEY, AUSTRALIA \u2013 31 August 2021<\/b><b>\u2013<\/b> Immutep Limited (ASX: IMM; NASDAQ: IMMP) (\u201c<b>Immutep<\/b>\u201d or the \u201c<b>Company<\/b>\u201d) is pleased to advise its Chinese partner for eftilagimod alpha (\u201cefti\u201d or \u201cIMP321\u201d), EOC Pharma (\u201cEOC\u201d) is planning to expand its clinical trial pipeline for efti (designated EOC202 in China) in China. <\/p>\n<p align=\"justify\">EOC is preparing to initiate a clinical trial of efti in combination with an anti-PD-1 therapy. The new trial is expected to commence in the first half of calendar year 2022.<\/p>\n<p align=\"justify\">The new trial builds on the latest promising data presented by Immutep at ASCO 2021 and on EOC\u2019s previously announced Phase II trial evaluating efti in combination with chemotherapy in metastatic breast cancer patients. This previously announced Phase II trial is currently expected to commence in the second half of calendar year 2021.<\/p>\n<p align=\"justify\">In addition, EOC has partnered with a contract development and manufacturing organisation in China. In August 2020, EOC received positive feedback from the Centre for Drug Evaluation (CDE), subordinate unit of China\u2019s National Medical Products Administration (NMPA) on its CMC comparability study results and recently completed an important 2000L manufacturing step for efti.<\/p>\n<p align=\"justify\">\n        <b>Dr. Xiaoming Zou, CEO of EOC Pharma, commented:<\/b> &#8220;Encouraged by our partner Immutep&#8217;s exciting clinical performance, we are ready to further exploit the clinical benefits of this promising drug in the IO realm.\u201d<\/p>\n<p align=\"justify\">\n        <b>Commenting on EOC\u2019s plans, Immutep CEO Marc Voigt said:<\/b> \u201cIt is great to see our growing confidence in efti is shared by our Chinese partner, EOC. Like Immutep, EOC is expanding its clinical trial pipeline, adding a new combination therapy study of efti with an anti-PD-1 drug. This is the same promising concept we are evaluating in TACTI-002 and TACTI-003, for example.\u201d <\/p>\n<p align=\"justify\">Efti is exclusively licensed to EOC for the territory of Greater China. EOC has full responsibility for the development and commercialisation of efti in the territory, and Immutep is eligible to receive development-based milestone payments and sales-based royalties. <\/p>\n<p align=\"justify\">\n        <b>About EOC Pharma<\/b><br \/>\n        <br \/>EOC Pharma is an integrated biopharmaceutical company focusing on the discovery, research, development, and commercialisation of innovative oncology products. With an insight-driven strategic planning capability and highly integrated product platform, EOC Pharma strives to build a portfolio of products with synergies from independent R&amp;D and partnering and enrich the product pipeline with first- and best-in-class oncology drugs to benefit the millions of patients who currently have limited access to high quality oncology treatments in China.<\/p>\n<p align=\"justify\">\n        <b>About Immutep <\/b>\n      <\/p>\n<p align=\"justify\">Further information can be found on the Company\u2019s website www.immutep.com or by contacting:<\/p>\n<p align=\"justify\">\n        <b>Australian Investors\/Media:<\/b><br \/>\n        <br \/>Catherine Strong, Citadel-MAGNUS<br \/>+61 (0)406 759 268; cstrong@citadelmagnus.com<\/p>\n<p align=\"justify\">\n        <b>U.S. Media:<\/b><br \/>\n        <br \/>Tim McCarthy, LifeSci Advisors<br \/>+1 (212) 915.2564;\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Em85fQEMj3dzmeM_YlQzPB2SH42qKl9fP8FO7uVXOAK37OnP1NLkeMb3Uq0JLn7w8Th90oyPEROdO3R87CCmDmIWs-_8ZNd55VbofQ-4CPI=\" rel=\"nofollow noopener\" target=\"_blank\">tim@lifesciadvisors.com<\/a><\/p>\n<p align=\"justify\">This announcement was authorised for release by the Board of Immutep Limited.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNzU5NSM0MzgxOTc3IzIwMTk4MzM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjU2ZjE0NTgtNmI5OC00NGY5LWFjYTQtZmQyY2FhNzQyZDY0LTEwMzE0MDU=\/tiny\/Immutep-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sydney, Aug. 31, 2021 (GLOBE NEWSWIRE) &#8212; SYDNEY, AUSTRALIA \u2013 31 August 2021\u2013 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (\u201cImmutep\u201d or the \u201cCompany\u201d) is pleased to advise its Chinese partner for eftilagimod alpha (\u201cefti\u201d or \u201cIMP321\u201d), EOC Pharma (\u201cEOC\u201d) is planning to expand its clinical trial pipeline for efti (designated EOC202 in China) in China. EOC is preparing to initiate a clinical trial of efti in combination with an anti-PD-1 therapy. The new trial is expected to commence in the first half of calendar year 2022. The new trial builds on the latest promising data presented by Immutep at ASCO 2021 and on EOC\u2019s previously announced Phase II trial evaluating efti in combination with chemotherapy in metastatic breast cancer patients. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immutep\u2019s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-532684","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immutep\u2019s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immutep\u2019s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Sydney, Aug. 31, 2021 (GLOBE NEWSWIRE) &#8212; SYDNEY, AUSTRALIA \u2013 31 August 2021\u2013 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (\u201cImmutep\u201d or the \u201cCompany\u201d) is pleased to advise its Chinese partner for eftilagimod alpha (\u201cefti\u201d or \u201cIMP321\u201d), EOC Pharma (\u201cEOC\u201d) is planning to expand its clinical trial pipeline for efti (designated EOC202 in China) in China. EOC is preparing to initiate a clinical trial of efti in combination with an anti-PD-1 therapy. The new trial is expected to commence in the first half of calendar year 2022. The new trial builds on the latest promising data presented by Immutep at ASCO 2021 and on EOC\u2019s previously announced Phase II trial evaluating efti in combination with chemotherapy in metastatic breast cancer patients. &hellip; Continue reading &quot;Immutep\u2019s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-31T12:03:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNzU5NSM0MzgxOTc3IzIwMTk4MzM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immutep\u2019s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline\",\"datePublished\":\"2021-08-31T12:03:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\\\/\"},\"wordCount\":458,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNzU5NSM0MzgxOTc3IzIwMTk4MzM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\\\/\",\"name\":\"Immutep\u2019s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNzU5NSM0MzgxOTc3IzIwMTk4MzM=\",\"datePublished\":\"2021-08-31T12:03:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNzU5NSM0MzgxOTc3IzIwMTk4MzM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMxNzU5NSM0MzgxOTc3IzIwMTk4MzM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immutep\u2019s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immutep\u2019s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Immutep\u2019s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline - Market Newsdesk","og_description":"Sydney, Aug. 31, 2021 (GLOBE NEWSWIRE) &#8212; SYDNEY, AUSTRALIA \u2013 31 August 2021\u2013 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (\u201cImmutep\u201d or the \u201cCompany\u201d) is pleased to advise its Chinese partner for eftilagimod alpha (\u201cefti\u201d or \u201cIMP321\u201d), EOC Pharma (\u201cEOC\u201d) is planning to expand its clinical trial pipeline for efti (designated EOC202 in China) in China. EOC is preparing to initiate a clinical trial of efti in combination with an anti-PD-1 therapy. The new trial is expected to commence in the first half of calendar year 2022. The new trial builds on the latest promising data presented by Immutep at ASCO 2021 and on EOC\u2019s previously announced Phase II trial evaluating efti in combination with chemotherapy in metastatic breast cancer patients. &hellip; Continue reading \"Immutep\u2019s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-31T12:03:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNzU5NSM0MzgxOTc3IzIwMTk4MzM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immutep\u2019s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline","datePublished":"2021-08-31T12:03:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/"},"wordCount":458,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNzU5NSM0MzgxOTc3IzIwMTk4MzM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/","name":"Immutep\u2019s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNzU5NSM0MzgxOTc3IzIwMTk4MzM=","datePublished":"2021-08-31T12:03:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNzU5NSM0MzgxOTc3IzIwMTk4MzM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMxNzU5NSM0MzgxOTc3IzIwMTk4MzM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuteps-chinese-partner-eoc-pharma-expands-efti-trial-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immutep\u2019s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/532684","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=532684"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/532684\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=532684"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=532684"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=532684"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}